3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Rectal Neoplasms
2
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
50
Cyclophosphamide
25
Carboplatin
25
Gemcitabine
20
Cisplatin
19
fludarabine
18
Nivolumab
17
Paclitaxel
16
Bevacizumab
15
Specimen Handling
14
Fluorouracil
11
Magnetic Resonance Spectroscopy
10
aldesleukin
9
Oxaliplatin
9
Irinotecan
9
Docetaxel
9
Biopsy
9
olaparib
8
Trastuzumab
8
durvalumab
7
atezolizumab
7
Hyperthermic Intraperitoneal Chemotherapy
7
Albumin-Bound Paclitaxel
7
Taxes
6
Leucovorin
6
Ipilimumab
6
Interleukin-2
6
Cetuximab
6
Capecitabine
6
130-nm albumin-bound paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Diphenhydramine
×
Gastrointestinal
×
Clear all
NCT04237090
2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3
Completed
27 enrolled